Assertio Therapeutics, Inc. News Releases http://investor.depomedinc.com/ Assertio Therapeutics, Inc. News Releases en Assertio Therapeutics Announces First-Quarter 2019 Financial Results http://investor.depomedinc.com/news-releases/news-release-details/assertio-therapeutics-announces-first-quarter-2019-financial -- Reports Neurology Franchise Net Sales of $26.3 million -- -- Commercialization Agreement Revenues of $30.9 million -- -- Raises 2019 Earnings Guidance Range and Confirms Neurology Franchise Net Sales Guidance -- -- Significant Debt Reduction -- LAKE FOREST, Ill. Wed, 08 May 2019 16:02:00 -0400 Assertio Therapeutics, Inc. News Releases 17821 Assertio Therapeutics to Report First Quarter 2019 Financial Results After The Close of Markets on Wednesday, May 8, 2019 http://investor.depomedinc.com/news-releases/news-release-details/assertio-therapeutics-report-first-quarter-2019-financial LAKE FOREST, Ill. , April 24, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release first quarter 2019 financial results on Wednesday, May 8, 2019 , after the close of markets. Following the announcement, the Company will host a conference call Wed, 24 Apr 2019 16:46:00 -0400 Assertio Therapeutics, Inc. News Releases 17806 Assertio Therapeutics Announces Appointment of Jay Galeota to Board of Directors http://investor.depomedinc.com/news-releases/news-release-details/assertio-therapeutics-announces-appointment-jay-galeota-board LAKE FOREST, Ill. , April 01, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that James (Jay) J. Galeota, Jr. has been appointed to the Company’s Board of Directors. Mr. Galeota most recently served as the President and Chief Operating Officer of G&W Mon, 01 Apr 2019 09:00:00 -0400 Assertio Therapeutics, Inc. News Releases 17756 Assertio Therapeutics Announces Favorable NUCYNTA® Patent Ruling http://investor.depomedinc.com/news-releases/news-release-details/assertio-therapeutics-announces-favorable-nucyntar-patent-ruling LAKE FOREST, Ill. , March 28, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that the United States Court of Appeals for the Federal Circuit has ruled in favor of Assertio with respect to the company’s patent litigation against three filers of Abbreviated New Thu, 28 Mar 2019 13:51:00 -0400 Assertio Therapeutics, Inc. News Releases 17746 Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2018 Financial Results http://investor.depomedinc.com/news-releases/news-release-details/assertio-therapeutics-announces-fourth-quarter-and-full-year -- Reports Neurology Franchise Annual Net Sales of $110.3 million , at the High End of Guidance Range -- -- Files NDA for Long-Acting Cosyntropin and Receives FDA Notification of Acceptance -- -- Issues Full-Year 2019 Guidance for Earnings and Neurology Franchise Net Sales -- LAKE FOREST, Ill. Wed, 06 Mar 2019 16:02:00 -0500 Assertio Therapeutics, Inc. News Releases 17706 Assertio Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results After The Close of Markets on Wednesday, March 6, 2019 http://investor.depomedinc.com/news-releases/news-release-details/assertio-therapeutics-report-fourth-quarter-and-full-year-2018 LAKE FOREST, Ill. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2018 financial results on Wednesday, March 6, 2019 , after the close of markets. Following the announcement, the Company will host a Thu, 21 Feb 2019 16:05:00 -0500 Assertio Therapeutics, Inc. News Releases 17696 Assertio Therapeutics Announces FDA Notification of Acceptance for Filing of 505(b)(2) NDA for Long-acting Cosyntropin http://investor.depomedinc.com/news-releases/news-release-details/assertio-therapeutics-announces-fda-notification-acceptance Company Anticipates Potential Market Launch by Early 2020 LAKE FOREST, Ill. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that it has received notification of acceptance for filing from the U.S. Food and Drug Administration ( FDA ) for its 505(b)(2) Tue, 19 Feb 2019 08:30:00 -0500 Assertio Therapeutics, Inc. News Releases 17676 Assertio Therapeutics Announces Appointment of Heather L. Mason to Board of Directors http://investor.depomedinc.com/news-releases/news-release-details/assertio-therapeutics-announces-appointment-heather-l-mason LAKE FOREST, Ill. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that Heather L. Mason has been appointed to the Company’s Board of Directors. Ms. Mason is a former executive vice president of Abbott Laboratories . Tue, 19 Feb 2019 08:00:00 -0500 Assertio Therapeutics, Inc. News Releases 17671 Assertio Therapeutics Announces Amendment of its Senior Secured Credit Facility http://investor.depomedinc.com/news-releases/news-release-details/assertio-therapeutics-announces-amendment-its-senior-secured Agreement Provides Greater Financial Flexibility as Company Continues to Reduce Debt LAKE FOREST, Ill. , Jan. 09, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that it has amended its Senior Secured Credit Facility, replacing the previous fixed adjusted EBITDA Wed, 09 Jan 2019 07:00:00 -0500 Assertio Therapeutics, Inc. News Releases 17561 Assertio Therapeutics Announces Submission of NDA for FDA Approval of Cosyntropin Depot http://investor.depomedinc.com/news-releases/news-release-details/assertio-therapeutics-announces-submission-nda-fda-approval -- Submission Advances Company’s Strategy to Build A New Orphan/Specialty Business and Aligns with Company’s Mission of Putting Patients First -- LAKE FOREST, Ill. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that it has submitted to the U.S. Thu, 20 Dec 2018 09:00:00 -0500 Assertio Therapeutics, Inc. News Releases 17546